Results 231 to 240 of about 536,044 (309)

Waste activated sludge high‐rate treatment of septage: Stabilization phase trials and comparison with winery wastewater treatment

open access: yesThe Canadian Journal of Chemical Engineering, EarlyView.
Performance evaluation of the waste activated sludge high‐rate (WASHR) process for septic wastewater treatment. Abstract The waste‐activated sludge high‐rate (WASHR) process is evaluated as a batch‐mode pre‐treatment for actual septage using a high‐rate contact stabilization (HRCS) approach.
Arman Shirali   +2 more
wiley   +1 more source

Early diagnostic accuracy of immature platelet fraction for sepsis: a systematic review and meta-analysis. [PDF]

open access: yesHematol Transfus Cell Ther
Wiranata S   +4 more
europepmc   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli   +17 more
wiley   +1 more source

Inter‐rater reliability and clinical utility of the BASED score in infantile epileptic spasms syndrome

open access: yesEpileptic Disorders, EarlyView.
Abstract Objective Hypsarrhythmia is the classical EEG pattern of children with infantile epileptic spasms syndrome (IESS). Multifocal spikes, slow waves of large amplitude, and chaoticity are its main characteristics, but these lack clear definitions, and the interrater reliability (IRR) is poor.
T. P. Cramer   +4 more
wiley   +1 more source

Real-world clinical outcomes of macrophage activation-like syndrome and hyperferritinemia in sepsis: a retrospective database analysis. [PDF]

open access: yesEClinicalMedicine
Ouranos K   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy